Core Viewpoint - Morgan Stanley has issued a report rating MicroPort Robotics-B (02252) as "Overweight" with a target price of HKD 41, highlighting the company's strong order growth and market expansion [1] Group 1: Product Performance - The core product "TUMI" has surpassed 200 cumulative orders, indicating an addition of approximately 20 orders since late January 2026, continuing the strong momentum observed from October 2025 to January 2026 [1] - The product range has expanded to over 50 countries and regions, up from over 40 by the end of December 2025, with 12 markets ordering more than five units, primarily led by emerging markets such as India and Brazil [1] Group 2: Market Position - MicroPort Robotics primarily provides surgical robots for minimally invasive surgeries, with "TUMI" and "HONGHU" being its core products in the laparoscopic and orthopedic fields, respectively [1] - "TUMI" is the first clinically validated Chinese laparoscopic surgical robot that matches the efficacy of the Da Vinci surgical system, which is currently the leading product from Intuitive Surgical in China and globally [1] - This achievement solidifies MicroPort Robotics' position as a leading domestic enterprise in China, allowing it to benefit from the trend of import substitution [1]